Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-β1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial
Título
Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-β1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial
Autor
Yaseen M. Arabi, Adel Alothman, Hanan H. Balkhy, Abdulaziz Al-Dawood, Sameera AlJohani, Shmeylan Al Harbi, Suleiman Kojan, Majed Al Jeraisy, Fahad Al-Hameed, Asim AlSaedi, Ghaleb A. Almekhlafi, Nisreen Murad Sherbeeni, Fatehi Elnour Elzein, Abdullah Almotairi, Ali Al Bshabshe, Ayman Kharaba, Robert A. Fowler, Ayed Y. Asiri, Abdullah M. Assiri, Hani A. Aziz Jokhdar, Ahmad M. Deeb, Ziad A. Memish, Sameeh Ghazal, Sarah Al Faraj, Yasser Mandourah, Jesna Jose, Abdulrahman Al Harthy, Mohammed Al Sulaiman, Ahmed Mady, Frederick G. Hayden, Mohamed Abdelzaher, Wail Bajhmom, Mohamed A. Hussein, and the Saudi Critical Care Trials group
Descripción
Abstract The MIRACLE trial (MERS-CoV Infection tReated with A Combination of Lopinavir/ritonavir and intErferon-β1b) investigates the efficacy of a combination therapy of lopinavir/ritonavir and recombinant interferon-β1b provided with standard supportive care, compared to placebo provided with standard supportive care, in hospitalized patients with laboratory-confirmed MERS. The MIRACLE trial is designed as a recursive, two-stage, group sequential, multicenter, placebo-controlled, double-blind randomized controlled trial. The aim of this article is to describe the statistical analysis plan for the MIRACLE trial. The primary outcome is 90-day mortality. The primary analysis will follow the intention-to-treat principle. The MIRACLE trial is the first randomized controlled trial for MERS treatment. Trial registration ClinicalTrials.gov, NCT02845843. Registered on 27 July 2016.
Fecha
2020
Materia
coronavirus, MERS, antiviral, Clinical trial, lopinavir/ritonavir, interferonβ-1b
Identificador
10.1186/s13063-019-3846-x
Fuente
Epidemiology and Health
Editor
Korean Society of Epidemiology
Cobertura
Medicine (General)
Archivos
Colección
Citación
Yaseen M. Arabi, Adel Alothman, Hanan H. Balkhy, Abdulaziz Al-Dawood, Sameera AlJohani, Shmeylan Al Harbi, Suleiman Kojan, Majed Al Jeraisy, Fahad Al-Hameed, Asim AlSaedi, Ghaleb A. Almekhlafi, Nisreen Murad Sherbeeni, Fatehi Elnour Elzein, Abdullah Almotairi, Ali Al Bshabshe, Ayman Kharaba, Robert A. Fowler, Ayed Y. Asiri, Abdullah M. Assiri, Hani A. Aziz Jokhdar, Ahmad M. Deeb, Ziad A. Memish, Sameeh Ghazal, Sarah Al Faraj, Yasser Mandourah, Jesna Jose, Abdulrahman Al Harthy, Mohammed Al Sulaiman, Ahmed Mady, Frederick G. Hayden, Mohamed Abdelzaher, Wail Bajhmom, Mohamed A. Hussein, and the Saudi Critical Care Trials group, “Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-β1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial,” SOCICT Open, consulta 18 de abril de 2026, https://www.socictopen.socict.org/items/show/5411.
Position: 12067 (23 views)